| Courtney Kay Wagner-bijak, MSN FNP-C | |
|
3406 College St Ste 100, Beaumont, TX 77701-4612 | |
| (409) 813-1677 | |
| (409) 813-1699 |
| Full Name | Courtney Kay Wagner-bijak |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 8 Years |
| Location | 3406 College St Ste 100, Beaumont, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215389267 | NPI | - | NPPES |
| 364744801 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 752722 (Texas) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | AP131287 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Beaumont Hospital | Beaumont, TX | Hospital |
| Christus Southeast Texas- St Elizabeth | Beaumont, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permian Premier Health Services Inc | 8426051293 | 104 |
News Archive
If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A University of Utah-led study using X-rays and neutron beams has revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.
› Verified 8 days ago
| Entity Name | Southeast Texas Medical Associates Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922001312 PECOS PAC ID: 1658281100 Enrollment ID: O20040405000787 |
News Archive
If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A University of Utah-led study using X-rays and neutron beams has revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.
› Verified 8 days ago
| Entity Name | Permian Premier Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285664763 PECOS PAC ID: 8426051293 Enrollment ID: O20060816000446 |
News Archive
If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A University of Utah-led study using X-rays and neutron beams has revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.
› Verified 8 days ago
| Entity Name | Beaumont Emergency Medicine Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881716983 PECOS PAC ID: 1951402767 Enrollment ID: O20070724000328 |
News Archive
If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A University of Utah-led study using X-rays and neutron beams has revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.
› Verified 8 days ago
| Entity Name | Diagnostic Group Integrated Healthcare System, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194061655 PECOS PAC ID: 1557506383 Enrollment ID: O20130328000104 |
News Archive
If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A University of Utah-led study using X-rays and neutron beams has revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Courtney Kay Wagner-bijak, MSN FNP-C 3406 College St Ste 200, Beaumont, TX 77701-4612 Ph: (409) 813-1677 | Courtney Kay Wagner-bijak, MSN FNP-C 3406 College St Ste 100, Beaumont, TX 77701-4612 Ph: (409) 813-1677 |
News Archive
If a team of American scientists are right, bone marrow transplants may become safer and more available to people in need of donations. In a new research paper appearing in the February 2010 print edition of the Journal of Leukocyte Biology (http://www.jleukbio.org), they explain how an anti-inflammatory agent called "ATL146e" may significantly improve the likelihood of success for bone marrow transplants by preventing or halting the progression of graft-versus-host disease, a complication of bone marrow transplants in which the donor marrow attacks the host. Although very rare, graft-versus-host disease can also occur after blood transfusions.
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Teva Pharmaceutical Industries Ltd. today announced results from the placebo group analyses of the ADAGIO study that were presented at the 62nd Annual Meeting of the American Academy of Neurology. The ADAGIO study stands out from other Parkinson's disease trials as it is the largest clinical study conducted in patients who were still in the very early stages of their disease course (average time from PD diagnosis of 4.5 months).
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, is pleased to announce that eligible people living with Human Immunodeficiency Virus (HIV) in England and Wales will soon have routine access to Vocabria (cabotegravir long-acting injection) developed by ViiV Healthcare in combination with Rekambys (rilpivirine long-acting injection), developed by Janssen Sciences Ireland UC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
A University of Utah-led study using X-rays and neutron beams has revealed the inner workings of a master switch that regulates basic cellular functions, but that also, when mutated, contributes to cancer, cardiovascular disease and other deadly disorders.
› Verified 8 days ago
Ruth Ngindu, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2950 Dowlen Rd, Beaumont, TX 77706 Phone: 866-389-2727 | |
Mrs. Monique Nichole Vannoy, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 810 Hospital Dr Ste 200, Beaumont, TX 77701 Phone: 409-212-5825 | |
Charlotte Stevens Lejune, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2830 Calder St, Beaumont, TX 77702 Phone: 409-236-7171 | |
Dawn Roque, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4347 Phelan Blvd, Beaumont, TX 77707 Phone: 409-767-9285 | |
Mrs. Carley Ann Jaynes, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 755 N 11th St Ste P3950, Beaumont, TX 77702 Phone: 409-892-0099 | |
Ms. Lynda Marie Few, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 3560 Delaware St # 601, Beaumont, TX 77706 Phone: 409-924-9666 | |
Jacqueline Nacole Dugas, FNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 740 Hospital Dr, Suite 300, Beaumont, TX 77701 Phone: 409-212-8111 |